Literature DB >> 23181387

Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry.

Olga Husson1, Harm R Haak, Laurien M Buffart, Willy-Anne Nieuwlaat, Wilma A Oranje, Floortje Mols, Johannes L Kuijpens, Jan Willem Coebergh, Lonneke V van de Poll-Franse.   

Abstract

BACKGROUND: Given the longevity of thyroid cancer patients, any impairment in health-related quality of life (HRQoL) during the follow-up period is of considerable concern. Therefore, the first aim of this study was to assess (thyroid cancer specific) HRQoL among long-term thyroid cancer survivors and to compare this with the HRQoL of an age- and sex-matched normative population. Secondly, our aim was to investigate which clinical and socio-demographic characteristics and thyroid cancer specific problems were associated with HRQoL.
MATERIAL AND METHODS: All patients diagnosed with thyroid cancer between 1990 and 2008, as registered in the Eindhoven Cancer Registry, received a survey on HRQoL (EORTC QLQ-C30) and disease-specific symptoms (THYCA-QoL). The scores were compared with age- and sex-matched cancer free controls (n = 800). A series of multiple linear regression analyses were conducted to investigate the independent associations between clinical, socio-demographic and thyroid cancer specific factors with HRQoL.
RESULTS: A total of 306 patients (86%) responded to the invitation. Thyroid cancer survivors had significantly lower scores on physical, role, emotional, cognitive and social functioning (p < 0.001) compared to the normative population after adjusting for comorbidities. Sympathetic problems [feeling chilly (52%), hot flushes (40%)], neuromuscular problems [cramp legs (43%) and pain joints/muscles (64%)] and abrupt attacks of fatigue (50%) were the most often reported thyroid cancer specific complaints. Thyroid cancer specific neuromuscular, concentration, sympathetic and psychological problems explained 41-58% of the variance in HRQoL. Clinical and socio-demographic factors explained a small part of the variance in (thyroid cancer specific) HRQoL (1-27%).
CONCLUSION: Long-term thyroid cancer survivors experience more symptoms and deteriorated HRQoL compared to the normative population. Thyroid cancer specific neuromuscular, sympathetic, concentration and psychological symptoms are stronger associated with HRQoL than clinical and socio-demographic factors alone. Awareness of these specific determinants of HRQoL could help health care practitioners to provide better supportive care.

Entities:  

Mesh:

Year:  2012        PMID: 23181387     DOI: 10.3109/0284186X.2012.741326

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  40 in total

Review 1.  Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis.

Authors:  Omar Saeed; Lori J Bernstein; Rouhi Fazelzad; Mary Samuels; Lynn A Burmeister; Lehana Thabane; Shereen Ezzat; David P Goldstein; Jennifer Jones; Anna M Sawka
Journal:  J Cancer Surviv       Date:  2019-04-04       Impact factor: 4.442

2.  Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics.

Authors:  Heide Götze; Sabine Taubenheim; Andreas Dietz; Florian Lordick; Anja Mehnert
Journal:  J Cancer Surviv       Date:  2018-08-10       Impact factor: 4.442

3.  Risk Factors for Decreased Quality of Life in Thyroid Cancer Survivors: Initial Findings from the North American Thyroid Cancer Survivorship Study.

Authors:  Briseis Aschebrook-Kilfoy; Benjamin James; Sapna Nagar; Sharone Kaplan; Vanessa Seng; Habibul Ahsan; Peter Angelos; Edwin L Kaplan; Marlon A Guerrero; Jennifer H Kuo; James A Lee; Elliot J Mitmaker; Jacob Moalem; Daniel T Ruan; Wen T Shen; Raymon H Grogan
Journal:  Thyroid       Date:  2015-12-01       Impact factor: 6.568

4.  Aging-Related Disease Risks among Young Thyroid Cancer Survivors.

Authors:  Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kimberly Herget; Jaewhan Kim; Anne C Kirchhoff; Christina Porucznik; Heidi Hanson; Marcus Monroe; Mia Hashibe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

5.  Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry.

Authors:  Olga Husson; Floortje Mols; Lonneke van de Poll-Franse; Jolanda de Vries; Goof Schep; Melissa S Y Thong
Journal:  Support Care Cancer       Date:  2015-01-06       Impact factor: 3.603

6.  Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.

Authors:  Eve M Roth; Carrie C Lubitz; John Shannon Swan; Benjamin C James
Journal:  Thyroid       Date:  2020-05-14       Impact factor: 6.568

7.  Use of Dietary Vitamin Supplements and Risk of Thyroid Cancer: A Population-Based Case-Control Study in Connecticut.

Authors:  Christopher Kim; Huang Huang; Nan Zhao; Catherine C Lerro; Min Dai; Yingtai Chen; Ni Li; Shuangge Ma; Robert Udelsman; Yawei Zhang
Journal:  Int J Vitam Nutr Res       Date:  2017-04-24       Impact factor: 1.784

Review 8.  The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma.

Authors:  Anthony R Glover; Justin S Gundara; Olov Norlén; James C Lee; Stan B Sidhu
Journal:  Gland Surg       Date:  2013-11

9.  A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma.

Authors:  Juan P Brito; Yasuhiro Ito; Akira Miyauchi; R Michael Tuttle
Journal:  Thyroid       Date:  2015-11-05       Impact factor: 6.568

10.  The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry.

Authors:  P A J Vissers; M S Y Thong; F Pouwer; M M J Zanders; J W W Coebergh; L V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2013-08-06       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.